Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 2/3 1

Status

Recruiting 2Completed 2

Sponsor Class

OTHER_GOV 2INDUSTRY 2

Study Type

Interventional 4Observational 3

Sponsor

Cancer Type

Gynecologic 4

Conditions

Ovarian Neoplasms 4Neoplasms 3Breast Neoplasms 3Recurrence 2Hypersensitivity 2Fallopian Tube Neoplasms 2Uterine Neoplasms 1Stomach Neoplasms 1Solid Tumor 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Prostatic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Neoplasms, Unknown Primary 1Neoadjuvant Therapy 1Lung Neoplasms 1Gastrointestinal Stromal Tumors 1Gastrointestinal Neoplasms 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1Colorectal Neoplasms 1Biliary Tract Neoplasms 1Adenocarcinoma 1

Interventions

Paclitaxel 326Carboplatin 318Bevacizumab 167Gemcitabine 106pembrolizumab 101liposomal doxorubicin 100Cyclophosphamide 96Topotecan 93Cisplatin 89olaparib 86niraparib 60Docetaxel 56Taxes 52Doxorubicin 50Drug Therapy 42fludarabine 40Filgrastim 39Nivolumab 37Etoposide 32Specimen Handling 31Magnetic Resonance Spectroscopy 29Immunoglobulin G 27Disulfides 27Peripheral Blood Stem Cell Transplantation 26Albumin-Bound Paclitaxel 25durvalumab 24aldesleukin 24Hyperthermic Intraperitoneal Chemotherapy 24Oxaliplatin 23Biopsy 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Ovarian Neoplasms × Poly(ADP-ribose) Polymerase Inhibitors × Clear all
NCT07472140 2026-03-16

PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer

N.N. Alexandrov National Cancer Centre

Phase 2/3 Recruiting
120 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05200260 2025-02-10

Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer

Shanghai Gynecologic Oncology Group

Phase 2 Recruiting
220 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01033123 2016-03-17

A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer

Sanofi

Phase 2 Completed
41 enrolled
Gynecologic

Hypersensitivity, Neoplasms, Ovarian Neoplasms, Recurrence

NCT01033292 2016-03-17

A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian Cancer

Sanofi

Phase 2 Completed
43 enrolled
Gynecologic

Hypersensitivity, Neoplasms, Ovarian Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡